Which has stronger earnings and valuation, EVO or IRON?

Evotec has higher revenue and earnings than Disc Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is EVO or IRON more profitable?

Disc Medicine has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Disc Medicine N/A -37.17% -33.65%

Does the media prefer EVO or IRON?

In the previous week, Disc Medicine had 11 more articles in the media than Evotec. MarketBeat recorded 15 mentions for Disc Medicine and 4 mentions for Evotec. Disc Medicine's average media sentiment score of 0.57 beat Evotec's score of 0.48 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 5 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EVO or RGC?

Evotec currently has a consensus target price of $3.00, suggesting a potential upside of 54.64%. Given Evotec's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evotec is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, EVO or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Which has preferable earnings and valuation, ATAI or EVO?

Evotec has higher revenue and earnings than Atai Beckley. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 646.32 -$660.05M -$2.23 N/A Evotec $891.97M 0.77 -$117.12M N/A N/A

Is ATAI or EVO more profitable?

Evotec has a net margin of -26.20% compared to Atai Beckley's net margin of -19,019.44%. Evotec's return on equity of -24.93% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -19,019.44% -89.79% -63.58% Evotec -26.20% -24.93% -11.35%

Does the media favor ATAI or EVO?

In the previous week, Evotec had 2 more articles in the media than Atai Beckley. MarketBeat recorded 4 mentions for Evotec and 2 mentions for Atai Beckley. Evotec's average media sentiment score of 0.48 beat Atai Beckley's score of 0.44 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, EVO or TARS?

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Tarsus Pharmaceuticals $451.36M 5.84 -$66.42M -$1.14 N/A

Does the media refer more to EVO or TARS?

In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 4 mentions for Evotec. Tarsus Pharmaceuticals' average media sentiment score of 0.85 beat Evotec's score of 0.48 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, KOD or EVO?

Evotec has higher revenue and earnings than Kodiak Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Evotec $891.97M 0.77 -$117.12M N/A N/A

Is KOD or EVO more profitable?

Kodiak Sciences has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Evotec -26.20% -24.93% -11.35%

Does the media favor KOD or EVO?

In the previous week, Kodiak Sciences had 2 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Kodiak Sciences and 4 mentions for Evotec. Kodiak Sciences' average media sentiment score of 1.46 beat Evotec's score of 0.48 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Evotec (EVO) Competitors

$1.94 +0.03 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.01 (+0.26%)

As of 07:06 PM Eastern

Compare

EVO vs. IRON, RGC, ATAI, TARS, and KOD

Should you buy Evotec stock or one of its competitors? MarketBeat compares Evotec with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evotec include Disc Medicine (IRON), Regencell Bioscience (RGC), Atai Beckley (ATAI), Tarsus Pharmaceuticals (TARS), and Kodiak Sciences (KOD).

How does Evotec compare to Disc Medicine?

Evotec (NASDAQ:EVO) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Disc Medicine has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Disc Medicine	N/A	-37.17%	-33.65%

Evotec presently has a consensus price target of $3.00, suggesting a potential upside of 54.64%. Disc Medicine has a consensus price target of $104.44, suggesting a potential upside of 36.87%. Given Evotec's higher probable upside, equities analysts clearly believe Evotec is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Evotec has higher revenue and earnings than Disc Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

In the previous week, Disc Medicine had 11 more articles in the media than Evotec. MarketBeat recorded 15 mentions for Disc Medicine and 4 mentions for Evotec. Disc Medicine's average media sentiment score of 0.57 beat Evotec's score of 0.48 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.8% of Evotec shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evotec has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

Disc Medicine beats Evotec on 7 of the 13 factors compared between the two stocks.

How does Evotec compare to Regencell Bioscience?

Evotec (NASDAQ:EVO) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Regencell Bioscience has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

5.8% of Evotec shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Regencell Bioscience has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Regencell Bioscience's return on equity of 0.00% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Regencell Bioscience	N/A	N/A	N/A

In the previous week, Evotec had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Evotec and 0 mentions for Regencell Bioscience. Evotec's average media sentiment score of 0.48 beat Regencell Bioscience's score of 0.00 indicating that Evotec is being referred to more favorably in the media.

Company	Overall Sentiment
Evotec	Neutral
Regencell Bioscience	Neutral

Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

Evotec currently has a consensus target price of $3.00, suggesting a potential upside of 54.64%. Given Evotec's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evotec is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evotec beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Evotec compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Evotec (NASDAQ:EVO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Atai Beckley presently has a consensus price target of $11.06, indicating a potential upside of 53.99%. Evotec has a consensus price target of $3.00, indicating a potential upside of 54.64%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Evotec had 2 more articles in the media than Atai Beckley. MarketBeat recorded 4 mentions for Evotec and 2 mentions for Atai Beckley. Evotec's average media sentiment score of 0.48 beat Atai Beckley's score of 0.44 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evotec has higher revenue and earnings than Atai Beckley.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	646.32	-$660.05M	-$2.23	N/A
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A

Atai Beckley has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

Evotec has a net margin of -26.20% compared to Atai Beckley's net margin of -19,019.44%. Evotec's return on equity of -24.93% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Evotec	-26.20%	-24.93%	-11.35%

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Evotec beats Atai Beckley on 10 of the 15 factors compared between the two stocks.

How does Evotec compare to Tarsus Pharmaceuticals?

Evotec (NASDAQ:EVO) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Evotec currently has a consensus target price of $3.00, indicating a potential upside of 54.64%. Tarsus Pharmaceuticals has a consensus target price of $90.17, indicating a potential upside of 47.04%. Given Evotec's higher probable upside, equities analysts plainly believe Evotec is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Tarsus Pharmaceuticals	$451.36M	5.84	-$66.42M	-$1.14	N/A

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Evotec's net margin of -26.20%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 4 mentions for Evotec. Tarsus Pharmaceuticals' average media sentiment score of 0.85 beat Evotec's score of 0.48 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

5.8% of Evotec shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Evotec on 12 of the 15 factors compared between the two stocks.

How does Evotec compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Evotec (NASDAQ:EVO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Evotec has higher revenue and earnings than Kodiak Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kodiak Sciences has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Kodiak Sciences had 2 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Kodiak Sciences and 4 mentions for Evotec. Kodiak Sciences' average media sentiment score of 1.46 beat Evotec's score of 0.48 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kodiak Sciences presently has a consensus price target of $48.14, suggesting a potential upside of 20.87%. Evotec has a consensus price target of $3.00, suggesting a potential upside of 54.64%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Kodiak Sciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Summary

Kodiak Sciences beats Evotec on 8 of the 13 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$679.49M	$9.21B	$6.86B	$12.45B
Dividend Yield	N/A	1.47%	2.60%	10.03%
P/E Ratio	N/A	59.52	280.72	24.99
Price / Sales	0.77	101.40	588.04	90.94
Price / Cash	N/A	25.63	28.64	34.82
Price / Book	0.75	5.12	11.02	6.21
Net Income	-$117.12M	$57.47B	$3.48B	$347.49M
7 Day Performance	1.04%	1.76%	0.56%	0.89%
1 Month Performance	-33.10%	-2.59%	-4.14%	-3.60%
1 Year Performance	-51.74%	16.88%	63.23%	20.46%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	3.7578 of 5 stars	$1.94 +1.6%	$3.00 +54.6%	-52.5%	$679.49M	$891.97M	N/A	4,553	Gap Up
IRON Disc Medicine	2.2228 of 5 stars	$73.88 -1.0%	$104.44 +41.4%	+30.6%	$2.83B	N/A	N/A	30	Earnings Report Upcoming Earnings Analyst Upgrade
RGC Regencell Bioscience	0.1007 of 5 stars	$5.48 -6.0%	N/A	-52.4%	$2.73B	N/A	N/A	10
ATAI Atai Beckley	2.7256 of 5 stars	$7.18 +0.1%	$11.38 +58.7%	+72.2%	$2.64B	$4.09M	N/A	80
TARS Tarsus Pharmaceuticals	3.823 of 5 stars	$60.56 +0.7%	$90.50 +49.5%	+44.7%	$2.61B	$535.08M	N/A	50	Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. IRON, RGC, ATAI, TARS, and KOD

How does Evotec compare to Disc Medicine?

Summary

How does Evotec compare to Regencell Bioscience?

Summary

How does Evotec compare to Atai Beckley?

Summary

How does Evotec compare to Tarsus Pharmaceuticals?

Summary

How does Evotec compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. IRON, RGC, ATAI, TARS, and KOD

How does Evotec compare to Disc Medicine?

Is EVO or IRON more profitable?

Do analysts prefer EVO or IRON?

Which has stronger earnings and valuation, EVO or IRON?

Does the media prefer EVO or IRON?

Do insiders & institutionals have more ownership in EVO or IRON?

Which has more volatility & risk, EVO or IRON?

Summary

How does Evotec compare to Regencell Bioscience?

Which has better valuation and earnings, EVO or RGC?

Do institutionals and insiders have more ownership in EVO or RGC?

Is EVO or RGC more profitable?

Does the media prefer EVO or RGC?

Which has more volatility and risk, EVO or RGC?

Do analysts rate EVO or RGC?

Summary

How does Evotec compare to Atai Beckley?

Do analysts rate ATAI or EVO?

Does the media favor ATAI or EVO?

Which has preferable earnings and valuation, ATAI or EVO?

Which has more risk and volatility, ATAI or EVO?

Is ATAI or EVO more profitable?

Do insiders & institutionals believe in ATAI or EVO?

Summary

How does Evotec compare to Tarsus Pharmaceuticals?

Which has more volatility and risk, EVO or TARS?

Do analysts rate EVO or TARS?

Which has stronger valuation and earnings, EVO or TARS?

Is EVO or TARS more profitable?

Does the media refer more to EVO or TARS?

Do insiders and institutionals believe in EVO or TARS?

Summary

How does Evotec compare to Kodiak Sciences?

Which has stronger valuation & earnings, KOD or EVO?

Do institutionals and insiders have more ownership in KOD or EVO?

Is KOD or EVO more profitable?

Does the media favor KOD or EVO?

Do analysts recommend KOD or EVO?

Which has more risk and volatility, KOD or EVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools